To further explore the possibility of CDC25B in the individualized treatment of HCC patients, we investigated the relationship between the drug half inhibitory concentration (IC50) of various chemotherapeutic agents for the treatment of HCC and the expression of CDC25B in hepatocellular carcinoma cells, and here, we have attached the IC50s of the clinically common drugs including sorafenib, cytarabine, cisplatin, axitinib, and fludarabine and the relationship of CDC25B expression. This evidence concerns the gene CDC25B and hepatocellular carcinoma.